文献速递免疫规划

异源ChAdOx1-nCoV19与BNT162b2疫苗接种的安全性和免疫原性:异源COVID-19疫苗接种结局的荟萃分析

Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes.
PubMed 文献 · Vaccine · 2023-03-30

该荟萃分析系统评估了异源ChAd/BNT疫苗接种方案的安全性和免疫原性,共纳入11项研究。与同源ChAd/ChAd接种相比,异源ChAd/BNT接种的中和抗体和抗刺突IgG的几何平均滴度比显著更高,但总不良反应发生率也更高,尤其是局部不良反应。异源ChAd/BNT接种与同源BNT/BNT接种的免疫原性和安全性相似。

要点

  • 异源ChAd/BNT接种的中和抗体和抗刺突IgG几何平均滴度比显著高于同源ChAd/ChAd接种。
  • 异源ChAd/BNT接种的总不良反应发生率高于同源ChAd/ChAd接种,尤其是局部不良反应。
  • 异源ChAd/BNT接种与同源BNT/BNT接种的免疫原性和安全性相似。

核心结论

  • 异源ChAd/BNT疫苗接种显示出强劲的免疫原性和可耐受的安全性。

研究设计与样本

  • 系统评价与荟萃分析,纳入11项研究,评估异源ChAd/BNT疫苗接种的免疫原性和安全性,研究注册于PROSPERO(CRD42021265165)。

主要发现

  • 与同源ChAd/ChAd接种相比,异源ChAd/BNT接种的中和抗体和抗刺突IgG的几何平均滴度比显著更高。
  • 异源ChAd/BNT接种的总不良反应发生率高于同源ChAd/ChAd接种,尤其是局部不良反应。
  • 异源ChAd/BNT接种与同源BNT/BNT接种的中和抗体和抗刺突IgG几何平均滴度比相似,安全性相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Here, we systematically assessed the safety and immunogenicity of the heterologous ChAd/BNT vaccination regimens. MATERIALS AND METHODS: We evaluated the immunogenicity by the geometric mean titers ratio (GMTR) of the neutralizing antibody and anti-spike IgG. The safety of heterologous ChAd/BNT vaccination was evaluated using the pooled risk ratios (RRs) calculated by the random-effects model about the adverse events. Our study was registered with PROSPERO, CRD42021265165. RESULTS: Eleven studies were included in the analyses. Compared to the homologous ChAd/ChAd vaccination, the heterologous ChAd/BNT vaccination showed significantly higher immunogenicity in terms of the neutralizing antibody and GMTR of anti-spike IgG, but at the same time displayed higher incidence of total adverse reactions, especially for the local adverse reactions. Moreover, heterologous ChAd/BNT vaccination showed similar immunogenicity to the homologous BNT/BNT vaccination (GMTR of neutralizing antibody and anti-spike IgG) and similar safety. DISCUSSION: Heterologous ChAd/BNT vaccination showed robust immunogenicity and tolerable safety.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hu Y, Wang Y, Shao T, et al. Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes. Vaccine. 2023. PMID: 37037708. doi:10.1016/j.vaccine.2023.03.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。